Hikma Pharmaceuticals (LON:HIK) Stock Passes Above 200-Day Moving Average - Here's What Happened

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,926.51 ($24.98) and traded as high as GBX 1,942 ($25.18). Hikma Pharmaceuticals shares last traded at GBX 1,920 ($24.90), with a volume of 415,904 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised Hikma Pharmaceuticals to a "buy" rating and boosted their target price for the company from GBX 2,100 ($27.23) to GBX 2,400 ($31.12) in a report on Monday, September 2nd.

Hikma Pharmaceuticals Price Performance

The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The company has a market cap of £4.22 billion, a price-to-earnings ratio of 2,944.62, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a fifty day simple moving average of GBX 1,945.08 and a two-hundred day simple moving average of GBX 1,926.51.

Hikma Pharmaceuticals Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, August 15th were given a $0.32 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a dividend yield of 1.37%. Hikma Pharmaceuticals's dividend payout ratio is currently 9,538.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.